Alto Neuroscience, Inc. cotiza a 24.15 USD y tiene una capitalización bursátil de $948M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and ser…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.65 | $-0.80 | $-0.45 | $-0.52 |
| Estimado | $-0.77 | $-0.50 | $-0.51 | $-0.64 |
| Sorpresa | +15.6% | -60.0% | +11.8% | +18.8% |
| Métrica | ANRO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -41.8% | -40.4% | -1.4% |
| ROA | -34.2% | -32.0% | -2.2% |
| Current Ratio | 15.69 | 2.84 | +12.85 |
| Debt / Equity | 0.11 | 0.28 | -0.17 |